XML 17 R6.htm IDEA: XBRL DOCUMENT v3.22.1
Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($)
Common Stock [Member]
Additional Paid-in Capital [Member]
Retained Earnings [Member]
AOCI Attributable to Parent [Member]
Total
Beginning balance, value at Sep. 30, 2020 $ 146 $ 40,472,229 $ (34,272,778) $ 190,161 $ 6,389,758
Beginning balance, shares at Sep. 30, 2020 14,570,105        
Stock option expense 4,507,298 4,507,298
Other comprehensive gain 1,656 1,656
Net loss (5,896,072) (5,896,072)
Exercise of stock options 9,180 9,180
Exercise of stock options, shares 6,000        
Equity securities issued for cash $ 3 2,683,977     2,683,980
Equity securities issued for cash, shares 324,959        
Ending balance, value at Dec. 31, 2020 $ 149 47,672,684 (40,168,850) 191,817 7,695,800
Ending balance, shares at Dec. 31, 2020 14,901,064        
Beginning balance, value at Sep. 30, 2020 $ 146 40,472,229 (34,272,778) 190,161 6,389,758
Beginning balance, shares at Sep. 30, 2020 14,570,105        
Other comprehensive gain         5,480
Net loss         (11,981,680)
Ending balance, value at Mar. 31, 2021 $ 178 61,549,965 (46,254,458) 195,641 15,491,326
Ending balance, shares at Mar. 31, 2021 17,820,390        
Beginning balance, value at Dec. 31, 2020 $ 149 47,672,684 (40,168,850) 191,817 7,695,800
Beginning balance, shares at Dec. 31, 2020 14,901,064        
Stock option expense 1,989,006 1,989,006
Other comprehensive gain 3,824 3,824
Net loss (6,085,608)   (6,085,608)
Restricted stock award issuance $ 1 870,999     871,000
Restricted stock award issuance, shares 137,215        
Equity securities issued for cash $ 28 11,017,276 11,017,304
Equity securities issued for cash, shares 2,782,111        
Ending balance, value at Mar. 31, 2021 $ 178 61,549,965 (46,254,458) 195,641 15,491,326
Ending balance, shares at Mar. 31, 2021 17,820,390        
Beginning balance, value at Sep. 30, 2021 $ 178 64,839,254 (52,824,808) 197,823 12,212,447
Beginning balance, shares at Sep. 30, 2021 17,820,390        
Exercise of warrants $ 4 1,721,014 1,721,018
Exercise of warrants, shares 384,447        
Stock option expense 1,124,187 1,124,187
Other comprehensive gain 32,688 32,688
Net loss (2,804,203) (2,804,203)
Ending balance, value at Dec. 31, 2021 $ 182 67,684,455 (55,629,011) 230,511 12,286,137
Ending balance, shares at Dec. 31, 2021 18,204,837        
Beginning balance, value at Sep. 30, 2021 $ 178 64,839,254 (52,824,808) 197,823 12,212,447
Beginning balance, shares at Sep. 30, 2021 17,820,390        
Other comprehensive gain         25,593
Net loss         $ (6,027,900)
Exercise of stock options, shares         14,000
Ending balance, value at Mar. 31, 2022 $ 185 69,098,937 (58,852,708) 223,416 $ 10,469,830
Ending balance, shares at Mar. 31, 2022 18,557,886        
Beginning balance, value at Dec. 31, 2021 $ 182 67,684,455 (55,629,011) 230,511 12,286,137
Beginning balance, shares at Dec. 31, 2021 18,204,837        
Stock option expense 935,447 935,447
Other comprehensive gain (7,095) (7,095)
Net loss (3,223,697) (3,223,697)
Warrant issuance costs (18,422) (18,422)
Common stock issued for cash, ATM offering 88,426 88,426
Common stock issued for cash, ATM offering, shares 42,448        
Common stock issued for Dripkit acquisition $ 2 386,842 386,844
Common stock issued for Dripkit acquisition, shares 178,681        
Exercise of stock options 12,600 12,600
Exercise of stock options, shares 14,000        
Restricted stock award issuance $ 1 9,589 9,590
Restricted stock award issuance, shares 117,920        
Ending balance, value at Mar. 31, 2022 $ 185 $ 69,098,937 $ (58,852,708) $ 223,416 $ 10,469,830
Ending balance, shares at Mar. 31, 2022 18,557,886